ALIM

Investor Moves

Name	Value	Action	Change	Price	Current Price
Mario GabelliGAMCO Investors $-144.2K ExitQ3 2024 $144k -- $5.54
Jim SimonsRenaissance Technologies $-1.0M ExitQ3 2024 $1M -- $5.54

Trade ALIM

About Alimera Sciences, Inc.

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.

CEO: Richard S. Eiswirth Jr.
IPO Date: Nov 4, 2019

Market Data

Open: $5.55
High: $5.56
Low: $5.53
Volume: 2.7M
Avg Volume: 907.3K
52W High: $5.65
52W Low: $2.61

Valuation

Market Cap: $301.3M
Enterprise Value: $356.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$89.8M
Revenue: $80.8M
Net Income: -$20.1M
Cash: $12.1M
Debt: $67.4M

Events

EarningsOct 24

EPS est. -0.01 · actual -0.06